Balakrishna Koneru

发表

Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma

Jo Lynne Rokita, D. Wheeler, J. Maris, 2020, Cancer Research.

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia

C. Reynolds, Min H. Kang, B. Maurer, 2019, Anti-cancer drugs.

Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies

C. Reynolds, Min H. Kang, M. R. Makena, 2017, Molecular Cancer Therapeutics.

Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies

C. Reynolds, Min H. Kang, C. Reynolds, 2020, Anti-cancer drugs.

The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma.

C. Reynolds, M. R. Makena, L. Lopez-Barcons, 2020, Anti-cancer drugs.

ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156

E. Cadogan, Aaron Smith, V. Pilla Reddy, 2021, Science Translational Medicine.

ALT Neuroblastoma Chemoresistance due to ATM Activation by Telomere Dysfunction is Reversible with the ATM Inhibitor AZD0156

E. Cadogan, Aaron Smith, V. Reddy, 2021, bioRxiv.

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models

Sung-Jen Wei, C. Reynolds, Min H. Kang, 2019, Molecular Cancer Therapeutics.

Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines

C. Reynolds, Min H. Kang, C. Reynolds, 2018, Pediatric blood & cancer.

Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.

C. Ronaghan, R. Rahman, Cody Eslinger, 2022, Cancer research.